Published in Drug Week, May 26th, 2006
This low point in revenues in recent years was primarily due to slowdowns and some cancellations in large-scale orders for key development pipeline and launched projects of pharmaceutical customers. Cash, cash equivalents and marketable securities were approximately $2 million at March 31, 2006.
Management anticipates that Synthetech's revenue will continue to be volatile from period to period. Variability in Synthetech's level of revenue is based primarily on the company's participation in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.